TTK Healthcare Ltd. Share Price

Overview

TTK Healthcare Ltd. share price is currently ₹1,050.25, up by ₹134.87 (14.73%) from its previous closing price of ₹915.38. The share price has gained 1.83% over the past month and declined -6.26% over the past year. The stock's 52-week low and high are ₹723.43 and ₹1,235.34, respectively. TTK Healthcare Ltd. has a market capitalisation of ₹ 1,302.53 Cr. The share price was last updated on 17 Nov 2026, 09:31 AM IST.

TTK Healthcare Ltd.
TTK Healthcare Ltd.
TTKHLTCARE
 ₹0.00
 ₹134.87
14.73%
Diversified
 ₹0.00(%)1D

Updated: 17 Nov 2026, 09:31:48 am IST

Market Data

Open Price

 ₹910.44

Prev. Close

 ₹915.38
 ₹910.44

Day Low

 ₹1,103.39

Day High

 ₹723.43

52 Week Low

 ₹1,235.34

52 Week High

DiversifiedDiversified
CategoryMicro Cap

Fundamentals

Quick Bite

Price To Earnings Ratio

5.37

Sector PE

34.97

PB Ratio

1.34

Sector PB

2.27

EPS

195.71

Dividend Yield

1.35

Today's Volume

216.852 K

5 Day Avg. Volume

48.441 K

PEG Ratio

-0.27

Market Cap.

₹ 1,302.53 Cr.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

ActionsEx-DateRecord-Date
DividendsFinal Dividend of 100% at ₹10/Share
17-Jul-202617-Jul-2026
DividendsFinal Dividend of 100% at ₹10/Share
18-Jul-202518-Jul-2025

Mutual Fund Ownership

Mutual Fund Holder
Apr 26
Shares held
May 26
Shares held
Motilal Oswal BSE 1000 Index Fund - Regular Plan - Growth10
10
no change

About TTK Healthcare Ltd. 👋

TTK Healthcare Limited is an India-based company providing consumer and healthcare products. The Company is engaged in the manufacture, marketing and distribution of Consumer, Animal Welfare and Food Products; Medical and Protective Devices. The Company's segments include Animal Welfare, Consumer Products, Medical Devices, Protective Devices, Foods, and Others. The Animal Welfare segment offers products for veterinary use. The Consumer Products segment comprises marketing and distribution of Woodward's Gripewater, Air Fresheners, among others. The Medical Devices segment include artificial heart valves, orthopedic implants, among others. The Foods segment comprises manufacturing and marketing of Food Products. Extruded products, such as papads, are offered under the brand name Fryums. The Protective Devices segment focuses on manufacturing and marketing of male contraceptives and other allied products. The Others segment includes the printing and publishing of maps and atlases.

Analyst Opinions

Insights from SEBI-registered analysts · updated live

Explore all →
Sunil Kotak

Sunil Kotak

30 Oct • 2:15 PM · SEBI-Registered Analyst

Q2FY27 Quarterly Result Announced for TTK Healthcare Ltd.

TTKHLTCARE SEBI RA – Shubh Consultancy – Sunil Kotak – INH000015826 Diversified company TTK Healthcare announced Q2FY27 results Financial Highlights: Revenue from operations: In Q2FY27, Standalone Revenue from operations stood at Rs 23,338.39 lakh, showing a QoQ drop of 9.39% from Rs 25,755.76 lakh in Q1FY27 and a YoY growth of 14.65% compared to Rs 20,356.77 lakh in Q2FY26; for H1FY27, it reached Rs 49,094.15 lakh, an increase of 14.17% YoY against Rs 42,999.75 lakh in H1FY26. Total income: In Q2FY27, Standalone Total income was Rs 25,212.46 lakh, reporting a QoQ decline of 7.09% from Rs 27,135.23 lakh in Q1FY27 but a YoY growth of 13.29% compared to Rs 22,254.06 lakh in Q2FY26; for H1FY27, it stood at Rs 52,647.59 lakh, recording a YoY expansion of 12.75% from Rs 46,694.60 lakh in H1FY26. Profit before tax (PBT): In Q2FY27, Standalone PBT expanded significantly to Rs 26,793.54 lakh, a QoQ surge of 828.45% from Rs 2,885.83 lakh in Q1FY27 and a YoY surge of 1,158.10% over Rs 2,129.69 lakh in Q2FY26; for H1FY27, PBT was Rs 29,679.47 lakh, rising 661.98% YoY from Rs 3,895.04 lakh in H1FY26 (boosted heavily by exceptional items). Profit after tax (PAT): In Q2FY27, Standalone PAT stood at Rs 22,297.26 lakh, indicating a QoQ surge of 947.84% over Rs 2,127.92 lakh in Q1FY27 and a YoY surge of 993.73% from Rs 2,038.64 lakh in Q2FY26; for H1FY27, it reached Rs 24,425.18 lakh, an increase of 631.60% YoY compared to Rs 3,338.58 lakh in H1FY26. Earnings Per Share (EPS) - Basic: In Q2FY27, Standalone Basic EPS was Rs 157.80, up 947.81% QoQ compared to Rs 15.06 in Q1FY27 and up 993.56% YoY compared to Rs 14.43 in Q2FY26; for H1FY27, it was Rs 172.86, showing a YoY growth of 631.53% over Rs 23.63 in H1FY26. All this is for information This is not a buy/sell recommendation. Thank you, Technofunda24

See More
Prameela Balakkala

Prameela Balakkala

6 Aug • 9:01 PM · SEBI-Registered Analyst

TTK Healthcare Q1: Profit Surge, Margin Expansion

TTKHLTCARE TTK Healthcare Q1 FY26 Results Net Profit: ₹213M vs ₹130M (YoY) ⬆️ Revenue: ₹2.6B vs ₹2.3B (YoY) ⬆️ EBITDA: ₹147M vs ₹27M (YoY) ⬆️ EBITDA Margin: 5.7% vs 1.2% (YoY) ⬆️ 📊 Fundamentals & Ratios Revenue: ~₹9.5B Net Profit: ~₹0.6B Debt-to-Equity: ~0.3 P/E Ratio: ~20–22 ROE: ~14% Dividend Yield: ~1.5% 🏦 Projects Pharma growth initiatives Medical device expansion Consumer wellness products R&D investments Sustainability programs ⚠️ Risks Margin sustainability Competitive intensity Regulatory compliance Demand cyclicality Capex execution

See More
Stock Reader

Stock Reader

17 Jun • 12:15 PM · SEBI-Registered Analyst

TTK Healthcare is an underfollowed company with a strong portfolio of trusted consumer healthcare brands and a debt-light balance sheet.

TTKHLTCARE The company operates in multiple segments including pharmaceuticals, medical devices, personal care, and foods, reducing dependence on any one business. Its brands enjoy high consumer recall, especially in products with recurring demand. As India's healthcare awareness, preventive care, and disposable incomes continue to rise, established healthcare brands are likely to benefit. The company also owns valuable real estate and has a long operating history, providing downside support. Management has maintained a conservative approach to capital allocation, and improving operational efficiency can significantly boost profitability due to operating leverage. TTK Healthcare has opportunities to expand through new product launches, premiumization, stronger distribution, and growth in e-commerce and modern retail. Any improvement in margins, coupled with steady revenue growth, could lead to meaningful earnings expansion. The stock is relatively less tracked compared to larger FMCG and pharma companies. If the market starts recognizing the value of its brands, assets, and earnings potential, valuation re-rating is possible. Key Bullish Triggers: • Strong legacy brands with customer trust. • Diversified healthcare business model. • Low debt and healthy financial position. • Rising demand for preventive healthcare in India. • Scope for margin expansion through efficiency. • Potential valuation re-rating due to underappreciated business. Risks to Watch: • Slow revenue growth in some segments. • Intense competition from larger FMCG and pharma companies. • Raw material cost fluctuations impacting margins. • Execution risk in scaling new products. Investment View: TTK Healthcare may not be a fast-moving momentum stock, but it has the characteristics of a steady compounder. If management delivers consistent earnings growth and improves return ratios, patient investors could benefit from both earnings growth and valuation re-rating over the next 3–5 years.

See More
Vibhu Jain

Vibhu Jain

15 Dec • 5:26 PM · SEBI-Registered Analyst

TTKHLTCARE

TTK Healthcare .’s fall to its 52-week low on 15 Dec 2025 reflects a combination of subdued sales growth, declining core profitability, and limited institutional interest. The stock’s technical indicators remain weak, trading below all major moving averages, while its valuation metrics suggest a premium relative to peers despite recent price declines. The company’s financial profile, including a low debt load and moderate ROE, provides some stability, yet the overall market response indicates ongoing challenges in delivering sustained shareholder value.

See More
Mayank Gupta

Mayank Gupta

2 Aug • 8:45 AM · SEBI-Registered Analyst

Earning Today

Earnings Today: Archean Chemical Industries, Ador Welding, Aeroflex Industries, Aptech, Bhagiradha Chemicals & Industries, Bharat Seats, Computer Age Management Services, Dalmia Bharat Sugar And Industries, Delhivery, Dhampur Sugar Mills, Dhanuka Agritech, Dolphin Offshore Enterprises (India), Edelweiss Financial Services, Forbes & Co, Glaxosmithkline Pharma, Grp, Hester Biosciences, Hindustan Zinc, Infibeam Avenues, lon Exchange (India), India Pesticides, Kirloskar Brothers, Lic Housing Finance, Mafatlal Industries, Medplus Health Services, Mold-Tek Tech, Mold-Tek Packaging, Nesco, Niit, Paushak, Psp Projects, Ram Ratna Wires, Rane Holdings, Saregama India, Sharda Motor Industries, Sil Investments, Sml Isuzu, Sudarshan Chemical Industries, Super Sales India, Tajgvk Hotels & Resorts, Tinna Rubber And Infra, Titan, Tamilnad Mercantile Bank, Ttk Healthcare, Upl, Valiant Communications, Zydus Wellness.

See More

News & Events

Frequently Asked Questions

What is the share price of TTK Healthcare Ltd.?

What is the market cap of TTK Healthcare Ltd.?

Should I buy TTK Healthcare Ltd. stock now?

What is the 52 week high and low of TTK Healthcare Ltd.?

Is the TTK Healthcare Ltd. stock good to buy?

Is TTK Healthcare Ltd. a good buy for the long term?

Is TTK Healthcare Ltd. overvalued or undervalued?

What is the PE and PB ratio of TTK Healthcare Ltd.?

Start Now